NCT06498050View on ClinicalTrials.gov

Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 10, 2025

Conditions
Diabetic Macular Edema
Interventions
DRUG

intravitreal injection of Brolucizumab 6 mg in study eye

After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.

Trial Locations (1)

510000

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
collaborator

Beijing Novartis Pharma

INDUSTRY

lead

Guangdong Provincial People's Hospital

OTHER